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Abstract: In this study we identified two 3′-coterminal RNA molecules in the 
pseudorabies virus. The highly abundant short transcript (CTO-S) proved to be encoded 
between the ul21 and ul22 genes in close vicinity of the replication origin (OriL) of the virus. 
The less abundant long RNA molecule (CTO-L) is a transcriptional readthrough product of 
the ul21 gene and overlaps OriL. These polyadenylated RNAs were characterized by 
ascertaining their nucleotide sequences with the Illumina HiScanSQ and Pacific 
Biosciences Real-Time (PacBio RSII) sequencing platforms and by analyzing their 
transcription kinetics through use of multi-time-point Real-Time RT-PCR and the PacBio 
RSII system. It emerged that transcription of the CTOs is fully dependent on the viral 
transactivator protein IE180 and CTO-S is not a microRNA precursor. We propose an 
interaction between the transcription and replication machineries at this genomic location, 
which might play an important role in the regulation of DNA synthesis. 
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1. Introduction 
Pseudorabies virus (PRV), an alphaherpesvirus related to the human pathogens herpes simplex  
virus (HSV) and varicella-zoster virus, infects a wide range of mammalian species, including 
experimental rodents and pigs, the reservoir of the virus. PRV is commonly used in investigations of 
the molecular pathogenesis of herpesviruses [1,2], for the mapping of neural circuits [3–5] and for the 
delivery of genetically encoded fluorescence activity markers to the central nervous system [6] and 
cardiomyocytes [7]. During the past few years, a large variety of non-coding RNAs (ncRNAs) have 
been revealed in both cellular organisms and viruses. Micro (mi)RNAs (the best known ncRNAs) 
typically act to decrease the target mRNA level [8]. These transcripts are generated through the 
processing of long precursor RNA molecules. MicroRNAs have been detected in α-herpesviruses 
(HSV: [9], and PRV: [10,11]), betaherpesviruses (human cytomegalovirus (HCVM): [12]), and 
gammaherpesviruses (Epstein-Barr virus (EBV): [13]). These transcripts have been shown to play 
various roles, including the switch between the latent and lytic phases, evasion of host immune 
surveillance and apoptosis inhibition [14]. Long ncRNAs (lncRNAs) are the most abundant group of 
ncRNAs [15]. Numerous protein-encoding genes have been shown to specify antisense (as)-lncRNAs 
transcribed from the complementary DNA strands as templates. Large proportions of the mouse and 
human genomes have recently been reported to express lncRNAs [16,17]. The functions of these 
transcripts are still largely unknown. Many lncRNAs are involved in the regulation of transcription, such 
as XIST [18] and HOTAIR [19], or post-transcriptional regulation [20], or have structural roles [17]. 
Studies of multiple model systems have revealed that lncRNAs can function as modular scaffolds, forming 
extensive networks between chromatin regulators and various ribonucleoproteins [21]. Several 
polyadenylated lncRNAs have recently been demonstrated to be highly abundant in herpesviruses, 
including RNA2.7 in HCMV, accounting for nearly half of the total gene expression in RNA-Seq 
studies [22], and the widely-studied PAN RNA in Kaposi’s sarcoma-associated herpesvirus [23], 
which has diverse roles during the viral life cycle [24]. The HSV latency-associated transcript (LAT) 
was the first identified as-lncRNA molecule [25] in alphaherpesviruses. A spliced 8.4-kb RNA, termed 
the long latency transcript (LLT), is generated from the complementary DNA strand of ie180 and ep0 
genes under the control of the LAT promoter of PRV [26]. The expression of as-lncRNAs has also 
been detected in some other HSV genes [27–29]. Moreover, several antisense long non-coding 
transcripts have been discovered in HCMV [30] and EBV [31]. 
2. Materials and Methods 
2.1. Cells and Viruses 
An immortalized porcine kidney epithelial cell line (PK-15) was used for the propagation of PRV. 
The cells were cultivated in Dulbecco’s modified Eagle medium supplemented with 5% fetal bovine 
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serum (Gibco Invitrogen, Carlsbad, CA, USA) and 80 μg gentamycin/mL at 37 °C under 5% CO2. The 
virus stock used for the kinetic analyses was prepared as follows: rapidly-growing semi-confluent  
PK-15 cells were infected at a multiplicity of infection (MOI) of 0.1 pfu/cell, and then incubated at  
37 °C under 5% CO2 until a complete cytopathic effect was observed. The infected cells were next 
frozen and thawed three times, followed by centrifugation at 10,000× g for 15 min. The titer of the 
virus stock was determined by using the same cell type. For the transcription kinetic experiments, cells 
were infected at either a low (0.1 pfu/cell) or a high MOI (10 pfu/cell), and then incubated for 1 h. This 
was followed by removal of the virus suspension and washing with phosphate-buffered saline. Infected 
cells were incubated for various periods of time following the addition of new medium to the cells. 
For Illumina DNA sequencing we mixed infected cells, which were incubated for 1, 2, 4, 6, 8, 10, 
12, 14, 16, 18, 20, 22 or 24 h. For PacBio analysis, infected cells were incubated 1, 2, 4, 6, 8 or 12 h p.i. 
For Real-Time RT-PCR, infected PK-15 cells were incubated for 1, 2, 4, 6, 8, 12 or 24 h. Mock-infected 
cells, which were otherwise treated in the same way as the infected cells, were used as controls. 
2.2. Generation of Recombinant Viruses 
The generation of ep0 and vhs gene-deleted viruses was described elsewhere (vhs-KO: [32],  
ep0-KO: [33]). Briefly, the desired viral genes were deleted by targeted mutagenesis using 
homologous recombination. Following subcloning of the target region of PRV, a lacZ gene 
expression-cassette was inserted in place of the genes to be deleted in both mutants. Mutant viruses 
were selected on the basis of the blue plaque phenotype. 
2.3. RNA Isolation for RNA-Seq and Real-Time RT-PCR 
Total RNA was purified by using the Nucleospin RNA kit (Macherey-Nagel), following the  
kit protocol. Cells were collected by low-speed centrifugation, lysed in a buffer containing the 
chaotropic ions needed for the inactivation of RNases and providing the conditions for the binding of 
nucleic acids to a silica membrane. Contaminating DNA was removed with RNase-free rDNase 
solution (included in the kit). The isolated total RNA was treated by means of the TURBO  
DNA-free™ Kit (Life Technologies) to remove potential residual DNA contamination. RNA concentration 
was determined by Qubit 2.0, and RNA integrity was assessed by using an Agilent 2100 Bioanalyzer. 
Samples were stored at −80 °C. 
2.4. Illumina HiScanSQ cDNA Sequencing 
Preparation of cDNA libraries—strand-specific total RNA libraries were prepared for sequencing 
through use of the Illumina ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre, Madison, WY 
USA) for random hexamer primed amplification and the sequencing of 2 × 100 bp fragments. For PA-Seq, 
a single-end library was constructed by using custom-anchored adaptor-primer oligonucleotides with 
an oligo(VN)T20 primer sequence. Anchored primers compensate for the loss in throughput due to the 
high fraction of reads containing solely adenine bases when conventional oligo(dT) primers are used. 
Transcriptome sequencing was performed on an Illumina HiScanSQ platform, generating  
~200 million paired-end reads of 100 bp length and ~105 million 50 bp single-end reads. The quality 
assessment of the raw read files was achieved with FastQC v0.10.1. Reads were aligned to the 
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respective host genome (Sus scrofa, assembly: Sscrofa10.2) and subsequently to the PRV genome 
(KJ717942.1) by using Tophat v2.09. [34]; ambiguous reads were discarded. For PA-Seq, mapping 
was carried out with Bowtie v2. [35], and polyA peaks were detected through the use of in-house 
scripts, based on the criteria of the presence of a PA signal in the 50 bp region upstream from the PA 
site and the presence of at least two consecutive adenine mismatches in at least 10 independent reads at 
the PA site. Annotation and visualization were carried out with the Artemis Genome Browser v15.0.0 [36]. 
Any GC bias of the alignments was inspected with the Bioconductor R package. 
2.5. PacBio RS II cDNA Sequencing 
2.5.1. PolyA RNA Purification 
Polyadenylated RNAs were isolated from the total RNA samples by using the Oligotex mRNA 
Mini Kit (Qiagen, Venlo, The Netherlands) according to the kit instructions for the Oligotex mRNA  
Spin-Column Protocol. 
2.5.2. cDNA Synthesis 
The PolyA RNA samples were quantified with the Qubit RNA HS Assay Kit (Life Technologies, 
Carlsbad, CA, USA) and converted to cDNAs with the SuperScript Double-Stranded cDNA Synthesis Kit 
(Life Technologies). RT reactions were primed with an Anchored Oligo(dT)20 primer (Life 
Technologies). The cDNAs were quantified with the Qubit HS dsDNA Assay Kit (Life Technologies) 
and quality was assessed with the Agilent 2100 bioanalyzer. 
2.5.3. Library Preparation, Sequencing and Data Collection 
SMRTbell libraries were generated by using the PacBio DNA Template Prep Kit 2.0 and the Pacific 
Biosciences template preparation and sequencing protocol for Very Low (10 ng) Input 2 kb libraries 
with carrier DNA (pBR322, Thermo Scientific, Waltham, MA, USA). SMRTbell templates were bound 
to polymerases by using the DNA polymerase binding kit XL 1.0 (part #100-150-800) and v2 primers. 
Polymerase-template complexes were bound to magbeads with the Pacific Biosciences MagBead 
Binding Kit, and sequencing was carried out on the Pacific Biosciences RSII sequencer with  
C3 sequencing reagents. Movie lengths were 180 min (one movie was recorded for each SMRT Cell). 
Subread filtering and alignment were carried out in SMRT Pipe v2.2.0. Visualization and data analysis 
were performed in SMRT Analysis v2.2.0. 
2.6. Normalization of PacBio Data with Mitochondrial Transcripts 
The read counts of viral transcripts at each time-point were normalized to mitochondrial read 
counts, aligned to the Sus scrofa 10.2 MT chromosome sequence. The following mitochondrial genes 
were used for the normalization: ATP6; ATP8; CYTB; ND1; ND2; ND3; ND4; ND4L; ND5; ND6; 
COX1; COX2 and COX3. While the degradation of cytoplasmic mRNAs during alphaherpesvirus 
infection has been previously shown [37,38], no such evidence is known for mtRNAs. Although recent 
studies have shown the steady decrease of mtDNA levels in Vero cells expressing the UL12.5 gene of 
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HSV-1 [39]. We chose the mtRNAs as reference RNAs because the UL12.5 gene is absent from the 
PRV genome. 
2.7. Reverse Transcription 
RT reactions were carried out with 70 ng of total RNA with the use of Superscript III enzyme (Life 
Technologies) and gene-specific primers or oligo(dT) primers. 
2.8. Real-Time PCR 
Real-Time PCR reactions were performed in a volume of 20 µL with Absolute QPCR SYBR Green 
Mix (Thermo Scientific) containing 7 µL of 10-fold diluted cDNA, 1.5 μL of forward and 1.5 μL of 
reverse primers (10 μM each; Table 1A). 28S ribosomal (r)RNA was used as a reference gene in each run. 
The PCR amplification conditions were as follows: 15 min at 95 °C for the enzyme activation, followed 
by 30 cycles of 94 °C for 25 s (denaturation), 60 °C for 25 s (annealing), and 72 °C for 6 s (extension). 
Table 1. Primer sequences for the Real-Time RT PCR analysis. 
 
Name Sequence (5′-3′) 
Genomic 
Position 
A CTO-S fw GACGATCCGGCGGTCCCA 63858–63875 
CTO-S rev GCGCCACAACCCGGAGC 63915–63931 
CTO-L fw GTG TCG CGG ACA GAG AAT GG 64604–64623 
CTO-L rev GGC CCA GTA CCT GTT TCA GC 64708–64727 
B T7-CTO-out fw TAATACGACTCACTATAGGGAGAGGTCTCTAAGGGGGAACCAG 63605–63626 
SP6-CTO-out rev ATTTAGGTGACACTATAGAAGNGCCGAAAAATTCGCACATACC 63989–64008 
(underline: T7 and SP6 promoter sequences, respectively). 
Relative expression ratios (R) were calculated via the following formula: 
𝑅 =
(𝐸sample∙max)
𝐶tsample∙max
(𝐸sample)
𝐶tsample
:
(𝐸ref∙max)
𝐶tref∙max
(𝐸ref)𝐶tref
 (1) 
where E is the amplification efficiency, Ct is the threshold cycle number, “sample” refers to the 
examined PRV transcript and “ref” refers to the 28S rRNA (internal control). The cDNAs were 
normalized to 28S cDNAs by using the Comparative Quantitation module of the Rotor-Gene Q 
software (Version 2.3.1, Qiagen), which automatically calculates the efficiency of the reaction. 
Thresholds were also set by the software. 
2.9. Treatment of Cells with CHX 
The requirement of de novo protein synthesis for CTO production was tested by cycloheximide 
(CHX) analysis. Cells were incubated in the presence or absence of 100 μg/mL CHX (Sigma-Aldrich, 
St. Louis, MO, USA) for 1 h prior to virus infection. Mock-infected cells otherwise treated in the same 
way as infected cells were used as controls. 
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2.10. Northern Blot Analysis 
Traditional Northern blot assay Total RNA was isolated from PK-15 cells through use of TRIzol 
reagent (Life Technologies) according to the manufacturer’s instructions. Samples were denatured in 
loading buffer for 5 min at 65 °C. Extracted RNA samples (10 ug) were fractionated in 
formaldehyde/1.2% agarose gel, transferred to a Nytran N membrane (Schleicher & Schuell 
BioScience, Dassel, Germany) by a capillary method and fixed by ultraviolet cross-linking. The 
membrane was probed by using the random primed PCR product or the total viral DNA with the 
DecaLabel DNA Labeling Kit (Fermentas, Vilnius, Lithuania). PCR reactions were carried out with 
AccuPrime GC-Rich DNA Polymerase (Life Technologies) according to the manufacturer’s 
recommendations (primer sequences Table 1B). The oligonucleotide probe was labeled with [α-32P]CTP. 
Filter prehybridization was carried out in 50% formamide, 0.5% SDS, 5× SSPE, 5× Denhardt’s 
solution and 20 μg/mL sheared, denatured salmon sperm. The probe was heated for 1 min at 95 °C. 
Overnight hybridization was carried out at 68 °C. Finally, the hybridization membranes were washed in 
2× SSC 0.1% SDS at 68 °C for ones 10 min, 0.5× SSC, 0.1% SDS at 68 °C for 10 min, 0.1× SSC 0.1% 
SDS at 68 °C for 10 min. 
Micro RNA Northern blot analysis two different PCR probes were used. Forward primers were 
linked with the T7 promoter sequence and reverse primers were linked with the SP6 promoter 
sequence (Table 1B). Samples (10 µg) were fractionated on denaturing 12% polyacrylamide gels 
containing 8 M urea, transferred to a Nytran N membrane (Schleicher & Schuell, Germany) by  
a capillary method and fixed by ultraviolet cross-linking. Prehybridization was carried out in 50% 
formamide, 0.5% SDS, 5× SSPE, 5× Denhardt’s solution and 20 μg/mL sheared, denatured salmon 
sperm DNA. Overnight hybridizations were performed in the same solution at 37 °C. An [α-32P]UTP-labeled 
RNA probe was used for the hybridization. Membranes were washed twice for 10 min with a solution 
containing 2× SSC, 0.1% SDS. 
3. Results 
3.1. Identification and Structural Characterization of Novel lncRNAs in PRV 
The PRV transcriptome was analyzed by means of the Illumina HiScanSQ and Pacific Biosciences 
(PacBio) RSII sequencing systems. Random hexamer-primed reverse transcription (RT) was used for 
Illumina sequencing, and oligo(dT)-primed (PA-Seq) RT for both platforms. With these techniques, 
we detected two novel 3′-coterminal transcripts located between the ul21 and ul22 genes, close to the 
OriL, termed CTOs. The length of the short intergenic lncRNA (CTO-S) is 286 base pairs (bp) and is 
mapped to bp-s 63673-63958 of the PRV reference genome KJ717942.1 (Figure 1). The attachment of 
adapter sequences to the Illumina RT primers allowed the analysis of transcription from both DNA 
strands separately. These investigations revealed that only one of the two DNA strands exhibits 
transcriptional activity at this genomic region. The long (CTO-L) transcript overlaps OriL, and maps to 
nucleotides (nt) 63673–66287 (2615 bp). CTO-L originates from the promoter of the ul21 gene and is 
produced by the continuation of the RNA polymerase molecule across the transcription termination 
sequences. CTO-L contains the entire ul21 gene sequence and is therefore a sense lncRNA. The 
promoter of the CTO-S transcript was identified in nucleotides 63952–63958 by the Tfsearch 
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algorithm with 96.8% confidence. An Oct1 transcription factor binding site was also discovered at 
98.3% confidence in the TransFac database [40]. 
 
Figure 1. Location of cto genes on the PRV genome. Both cto transcripts (CTOs) are 
polyadenylated RNAs with a common 3′ termination. CTO-L is generated by the 
continuation of transcription after the termination signals of the ul21 gene. OriL is the 
replication origin of in the UL region of viral DNA mapped between the ul21 and ul22 genes. 
3.2. Transcriptional Analysis of CTO 
3.2.1. Illumina RNA-Seq Analysis 
We combined transcripts isolated from consecutive time-points of viral infection for Illumina sequencing. 
CTO-S proved to exhibit a very high expression, with an RPKM (reads per kilobase per million) value 
of 1.6 × 106 in the random-hexamer primed library, and 45.9% of the total read count in PA-Seq, 
making this transcript by far the most abundant viral RNA molecule. CTO-L produced only 0.13% of 
the total reads in the random hexamer-primed library (RPKM = 5 × 10−4). However, pA-Seq produces 
more informative data than random hexamer-primed sequencing: in the former case the read numbers 
are in strict correlation only with the transcript abundance, whereas in the latter case they correlate 
with the transcript lengths too. 
3.2.2. PacBio RNA-Seq Analysis 
For the analysis of the transcription kinetics of the CTO length variants, we applied the PacBio  
RS II system, which is capable of generating significantly longer read lengths than those of  
second-generation technologies, such as Illumina. The CTO expression was analyzed at 1, 2, 4, 6, 8 or 12 h 
by using high [10 plaque forming unit (pfu)/cell] infection conditions. Due to template quantity we 
used the very low input protocol for the template preparation and sequencing, which is not optimal for 
the detection of small (<700 nt) transcripts, and we therefore observed a very strong bias against CTO-S. 
Due to the low sensitivity of this technique for small DNA fragments, the real proportion of the two 
transcripts cannot be precisely ascertained through its use. However, the data obtained could be used to 
compare the transcription kinetics in the two transcripts (Figure 2). The viral RNA reads were 
normalized with the pig mitochondrial RNAs, which are thought to resist degradation by the RNase 
activity of viral proteins. No reads were obtained for either of the CTO transcripts in the first hour of 
infection. A low amount of CTO-L was detected 2 h post-infection (p.i.). The CTO-S transcript 
appeared in only the 4 h p.i. samples (Figure 2A). The logarithmic plots demonstrate a slight increase 
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in the dynamics of transcriptions between 4 and 6 h p.i. in both transcripts (Figure 2B), followed by an 
elevated expression rate, especially in CTO-L, which increased very steeply after 6 h p.i.. However, 
analysis of the transcriptional activity normalized to the copy number of PRV DNA (determined by 
Real-Time RT-PCR) demonstrated that the expression from individual DNA molecules was highest at 
8 h p.i. for both transcripts (Figure 2C). F ig u re  2 A
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Figure 2. Transcription kinetics of CTO transcripts. The relative abundances of transcripts 
are depicted on a linear (A) and a logarithmic (B) scale. All RNA reads obtained by 
PacBio sequencing were normalized with mitochondrial RNAs. The transcriptional activity 
of the CTOs was also analyzed by normalizing the data with the relative amount of viral 
DNAs (C). 
We examined whether the efficiency of transcriptional readthrough varied in time by comparing the 
amounts of CTO-L and ul21 mRNA (Figure 3A,B). The data revealed that the ratio of CTO-L to the 
ul21 transcript increased continuously in time. An examination as to whether this was simply due to  
a higher transcription rate of individual ul21 genes did not indicate an ycorrelation between the 
readthrough efficiency and the transcriptional activity of this gene when the transcript reads were 
normalized with the DNA copy number (Figure 3C). This suggests that the efficiency of the 
recognition of transcriptional termination sequences might be regulated by a specialized mechanism. 
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Figure 3. Comparison of the amounts of ul21 and CTO-L transcripts. CTO-L is a readthrough 
product of the ul21 gene. (A) shows the transcriptional kinetics of the two transcripts, while 
(B) shows the change in readthrough efficiency with time. All RNA reads obtained by 
PacBio sequencing were normalized with mitochondrial RNAs. (C) shows the 
transcriptional activity normalized to the viral genome. 
3.2.3. Multi-Time-Point Real-Time RT-PCR Analysis of CTOs in Wild-Type (wt) and Mutant 
Backgrounds 
Wild-type PRV 
Strand-specific priming-based RT was used for the kinetic assay of the abundant CTO-S transcript 
in both low-titer (0.1 pfu/cell) and high-titer (10 pfu/cell) infection. The method used for the 
calculation of relative expression ratios (R) was as described earlier [41]. Real-Time RT-PCR analyses 
confirmed the PacBio and Illumina RNA-Seq results, showing that practically no transcription 
occurred in the first 2 h of the viral life cycle in the genomic region encoding CTO-S (Figure 3A). In the 
high-titer infection, CTO-S reached very high levels by 4 h p.i. (Figure 4A), which means that the 
expression of this transcript is initiated sometime between 2 and 4 h p.i. In the low-titer experiment, 
however, CTO-S was expressed at a very low level at 4 h, but reached a high level by 6 h p.i. (Figure 
4B). Thus, there is a shift in the expression kinetics of CTO-S transcripts in low-pfu as compared with 
high-pfu experiments. The CTO-L expression was examined by using strand-specific primers for the 
reverse transcriptions at 1, 2, 4, 6, 8, 12, 18 and 24 h at high-titer infection (Figure 4C) and 1, 2, 4, 6 and 
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8 h at low-titer infection (Figure 4D). There was no significant expression until 4 h p.i., which 
confirmed the PacBio sequencing data. F ig u re  4 A
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Figure 4. The change in relative expression ratio (R) of the CTO transcripts with time, 
determined by Real-Time RTR-PCR. (A). CTO-S: High-titer (10 pfu/cell) infection. The 
cDNAs were generated by reverse transcription of CTO-S transcripts through the use of 
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gene-specific or oligo(dT) primers. (B). CTO-S: Low-titer (0.1 pfu/cell) infection.  
The cDNAs were generated by reverse transcription of CTO-S transcripts through the use 
of gene-specific or oligo(dT) primers. (C). CTO-L: High-titer (10 pfu/cell) infection.  
The cDNAs were generated by reverse transcription of CTO-S transcripts through the use 
of gene-specific or oligo(dT) primers. (D). CTO-L: Low-titer (0.1 pfu/cell) infection.  
The cDNAs were generated by reverse transcription of CTO-S transcripts through the use 
of gene-specific or oligo(dT) primers. (E). Expression of CTO-S in vhs-KO background 
following high-titer infection. (F). Expression of CTO-S in ep0-KO background following 
high-titer infection.  
Mutant PRVs 
Two mutant viruses were used to analyze the CTO-S and CTO-L transcription kinetics in order to 
evaluate the potential effects of mutations on the expression kinetics of this transcript. The levels of 
the two transcripts were higher than that of the wt virus in the vhs-KO virus (Figure 4E), which is not 
surprising since the virion host shut-off (VHS) protein plays a role in the destabilization of RNA 
molecules [42]. We earlier reported similar transcription kinetics for the rest of the PRV genes [32]. 
The expression kinetics of the CTOs in the ep0-KO (ep0: early protein 0) background, however, 
exhibits an atypical pattern since the transcript levels of other late genes of the wt virus are generally 
higher than those of the ep0-null mutant virus, which is not the case for these lncRNAs (Figure 4F). 
Additionally, in contrast to the wt virus, the level of CTO-S and CTO-L is relatively high at 2 h p.i. in 
this mutant virus. Thus, EP0 appears to exert a down-regulatory effect on the transcription of CTOs 
throughout the whole life cycle of the virus. 
3.3. CTO Expression is Controlled by the IE180 Transactivator of PRV 
The transcription of PRV genes is controlled by the IE180 transactivator protein. Cycloheximide (CHX), 
an inhibitor of protein synthesis in eukaryotic cells, completely blocked gene expression, except in the 
ie180 gene itself and two as-lncRNA-encoding genes, LAT and LLT. The repression of CTO 
expression in the presence of CHX indicates that the transcription of these molecules is fully 
dependent on IE180 (Figure 5). Earlier we had shown that ul21 gene expression was completely 
repressed by CHX treatment [41], which—due to their sharing a common promoter—also resulted in 
the silencing of CTO-L transcription. 
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Figure 5. Analysis of transcription following CHX treatment of infected cells.  
The ie180 gene is not repressed by cycloheximide (CHX), but CTO-S is totally blocked by 
this protein synthesis inhibitor, the reason for this being that CTO-S requires the IE180 
protein for its expression. 
3.4. CTO Expression in the Presence of an Inhibitor of DNA Replication 
We additionally investigated the effect of phosphonoacetic acid (PAA), an inhibitor of DNA 
synthesis, on the transcription kinetics of CTO-S. The method of calculation for the evaluation of the 
repressive effect of PAA on the transcription of the individual genes was published earlier [41]:  
Ri-PAA = R6h-PAA/R6h-UT. In the present study, the average Ri-PAA values were found to be 0.717 for early 
genes and 0.113 for late genes. The value of Ri-PAA = 0.184 for CTO-S and Ri-PAA = 0.361 for CTO-L 
confirmed the result of our kinetic analyses in non-treated samples: these transcripts are expressed with 
late kinetics. 
3.5. Northern Blot and in Silico Analyses Revealed that CTO-S is not a miRNA Precursor 
Our investigation of whether CTO-S might be a miRNA precursor by using microRNA Northern blot 
analysis, however, did not detect any transcript with miRNA size in this genomic region (data not shown). 
Conversely, CTO-S RNA was detected by using traditional Northern blot analysis (Figure S1). Due to 
the very low copy number, we could not detect CTO-L by Northern blot analysis, however, the 
existence of this transcript was verified by four independent techniques (PacBio PA-seq, two Illumina 
RNA-seq methods and Real-time RT-PCR). Sequence analysis of CTO by using the pre-microRNA 
hairpin prediction tools miRNAFold [43] and miPred [44] yielded negative results in each case. 
Moreover, previous studies of the miRNA expression in PRV in both porcine dendritic [10] and 
epithelial [11] cell lines failed to detect miRNAs from the genomic region of CTO. 
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4. Discussion 
In this study we report the identification and characterization of two lncRNAs of pseudorabies virus. 
The two transcripts share a common poly(A) signal. CTO-S, a short intergenic lncRNA molecule is 
found to be very abundant, but is not expressed in the first 2 h of viral infection. We have 
demonstrated that the expression of CTO-S is controlled by the virally-encoded IE180 transactivator. 
CTO-L is expressed at a relatively low level, produced from the promoter of the ul21 gene through 
occasional transcriptional readthrough events across the transcription termination signal of this gene. 
The levels of CTO-S transcripts in the mutant viruses are higher at every time point than in the wt 
PRV, indicating a role of these gene products in the stability and/or the regulation of these molecules 
at the level of transcription. The vicinity of CTO-S to OriL and the overlap of CTO-L with OriL 
suggest a role of this genomic region in the regulation of DNA replication, which may be based on the 
interference between the transcriptional and replication machineries, as suggested by Huvet et al. [45]. 
Others did not verify the Huvet model, at least in human cells [46]. Despite this, interference between 
the two apparatuses may be an existing mechanism; the RNA polymerase molecules transcribing 
CTO-L might clash with DNA polymerase, thereby preventing the progress of replication in one of the 
two directions (Figure 6). It has been hypothesized, but never proved, that the synthesis of 
alphaherpesvirus DNAs starts with δ-type replication, which is followed by a switch to sigma-type 
replication generating concatemers [47]. The transcription of CTO-S may facilitate replication in 
another way, through separation of the two DNA strands, thereby helping the progression of DNA 
polymerase in one direction. In this scenario, the lack of CTO expression in the first few hours of the 
viral life cycle allows bidirectional δ-type replication; later, the process of CTO transcription itself 
makes the replication unidirectional through the two mechanisms proposed above. If there is no δ-type 
replication, and the viral DNA synthesis starts with CTO transcription itself, this makes the replication 
unidirectional through the two mechanisms proposed above. If there is no δ-type replication, and the 
viral DNA synthesis starts with concatemer formation immediately, the above putative mechanism 
might also contribute to the unidirectionality of DNA synthesis. Overall, extensive transcriptional 
activity near oriL potentially exerts an effect on the DNA replication by determining the orientation of 
the DNA synthesis and perhaps contributing to the switch from bidirectional to unidirectional replication. 
The polyadenylation of CTO-S indicates that this transcript may have additional function(s) in the 
life cycle of the virus. These transcripts do not have an essential role in the viral replication since two 
strains (TJ [48] and ZJ01 [49]) contain deletions at this genomic region. 
In this putative mechanism, the transcripts are merely by-products. It has been shown in a variety of 
organisms that a similar mechanism based on the clash between two RNA polymerase molecules in the 
overlapping region may have a regulatory effect on the transcription through transcriptional  
interference [50–52]. 
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Figure 6. A proposed model for the interactions between the replication and transcription 
machineries. (A) There is no CTO expression in the early stage of infection, and this 
allows the bidirectional synthesis of DNA (δ type replication). (B) Later, the transcription 
machineries of the CTOs facilitate unidirectional DNA replication through two 
mechanisms: (1) the DNA polymerase collides with the RNA polymerase synthesizing 
CTO-L, thereby halting the progression and/or preventing the assembly of the replication 
machinery (right to OriL); and (2) RNA polymerase transcribing the CTO-S (or CTO-L) 
facilitates the progression of DNA polymerase in one way through unwinding of the two 
DNA strands (left to OriL). For the sake of simplicity, the DNA synthesis from the lagging 
strand is not depicted. 
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